MedWatch

Sanofi: We will definitely make an objection

The pharmaceutical company Sanofi, which produces the insulin analog Lantus, fears that the proposed re-evaluation of the Danish reimbursement-rules for diabetes medicine will lead to fewer patients using their drug. The company will now be looking into fresh data.

Foto: Sanofi/PR

Frank Stærmose fears that last week’s proposed reimbursement-changes will lead to fewer patients using the insulin analog Lantus.

He is Business Unit Director in Sanofi Denmark, the company behind the drug – a drug that he and the company believe is being used sensibly at present.

Allerede abonnent? Log ind.

Læs hele artiklen

Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Relaterede

Seneste nyt

MedWatch job

Se flere jobs

Se flere jobs

Watch job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier